Fenofibrate induces ketone body production in melanoma and glioblastoma cells

Frontiers in Endocrinology

Volumn 7, Issue FEB, 2016, Pages

  Grabacka, Maja M ^a   Wilk, Anna ^b   Antonczyk, Anna ^a   Banks, Paula ^a   Walczyk Tytko, Emilia ^a   Dean, Matthew ^c   Pierzchalska, Malgorzata ^a   Reiss, Krzysztof ^c  

^a UNIVERSITY OF AGRICULTURE IN KRAKOW   (Poland)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 hydroxy 3 methylglutaryl CoA synthetase 2; Beta hydroxybutyrate; Peroxisome proliferator activated receptor alpha; Transketolase

Indexed keywords

3 HYDROXYBUTYRIC ACID; FENOFIBRATE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; GLIOBLASTOMA; GROWTH DISORDER; IMMUNOBLOTTING; KETOGENESIS; MELANOMA; NONHUMAN; OXYGEN CONSUMPTION; PLASMID; PROTEIN EXPRESSION;

EID: 84962543245     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2016.00005     Document Type: Article

References (80)

1. Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan M, Gonzalez FJ, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 100(7):4012-7. doi: 10.1073/pnas.0730870100.
2. Vila-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J Biol Chem (2011) 286(23):20423-30. doi:10.1074/jbc.M111.235044.
3. Blazquez C, Woods A, de Ceballos ML, Carling D, Guzman M. The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes. J Neurochem (1999) 73(4):1674-82. doi:10.1046/j.1471-4159.1999.731674.x.
4. Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology (2014) 146(2):539.e-49.e. doi:10.1053/j.gastro.2013.10.059.
5. Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 279(27):27849-54. doi:10.1074/jbc.M404087200.
6. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal (2010) 8:e002. doi:10.1621/nrs.08002.
7. Porta N, Vallee L, Lecointe C, Bouchaert E, Staels B, Bordet R, et al. Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties. Epilepsia (2009) 50(4):943-8. doi:10.1111/j.1528-1167.2008.01901.x.
8. Yamamoto K, Fukuda N, Zhang L, Sakai T. Altered hepatic metabolism of fatty acids in rats fed a hypolipidaemic drug, fenofibrate. Pharmacol Res (1996) 33(6):337-42. doi:10.1006/phrs.1996.0046.
9. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab (2007) 5(6):426-37. doi:10.1016/j.cmet.2007.05.002.
10. Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem (1994) 269(29):18767-72.
11. Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha. EMBO J (1998) 17(23):6972-8. doi:10.1093/emboj/17.23.6972.
12. Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab (2013) 18(6):920-33. doi:10.1016/j.cmet.2013.11.013.
13. Hirschey MD, Shimazu T, Capra JA, Pollard KS, Verdin E. SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2. Aging (Albany NY) (2011) 3(6):635-42.
14. Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE. FASEB J (2010) 24(6):1914-24. doi:10.1096/fj.09-149765.
15. Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem J (1999) 338(Pt 3):569-82. doi:10.1042/bj3380569.
16. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem (2001) 276(30):27950-8. doi:10.1074/jbc.M100258200.
17. Cahill G Jr, Felig P, Owen O, Wahren J. Metabolic adaptation to prolonged starvation in man. Nord Med (1970) 83(3):89.
18. Cahill GF Jr. Starvation in man. N Engl J Med (1970) 282(12):668-75. doi:10.1056/NEJM197003192821209.
19. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr (2006) 26:1-22. doi:10.1146/annurev.nutr.26.061505.111258.
20. Schonfeld P, Reiser G. Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab (2013) 33(10):1493-9. doi:10.1038/jcbfm.2013.128.
21. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids (2004) 70(3):309-19. doi:10.1016/j.plefa.2003.09.007.
22. Kozak LP, Harper ME. Mitochondrial uncoupling proteins in energy expenditure. Annu Rev Nutr (2000) 20:339-63. doi:10.1146/annurev.nutr.20.1.339.
23. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. IUBMB Life (2001) 51(4):241-7. doi:10.1080/152165401753311780.
24. Cahill GF Jr, Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc (2003) 114:149-63. discussion 162-3.
25. Tisdale MJ, Brennan RA. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer (1983) 47(2):293-7. doi:10.1038/bjc.1983.38.
26. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 104(49):19345-50. doi:10.1073/pnas.0709747104.
27. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 105(48):18782-7. doi:10.1073/pnas.0810199105.
28. Maurer GD, Brucker DP, Bahr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer (2011) 11:315. doi:10.1186/1471-2407-11-315.
29. Patel MS, Russell JJ, Gershman H. Ketone-body metabolism in glioma and neuroblastoma cells. Proc Natl Acad Sci U S A (1981) 78(11):7214-8. doi:10.1073/pnas.78.11.7214.
30. Skinner R, Trujillo A, Ma X, Beierle EA. Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg (2009) 44(1):212-6. discussion 216, doi:10.1016/j.jpedsurg.2008.10.042.
31. Poff AM, Ari C, Arnold P, Seyfried TN, D'Agostino DP. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer (2014) 135(7):1711-20. doi:10.1002/ijc.28809.
32. Magee BA, Potezny N, Rofe AM, Conyers RA. The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci (1979) 57(5):529-39. doi:10.1038/icb.1979.54.
33. Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab (2014) 2:18. doi:10.1186/2049-3002-2-18.
34. Tisdale MJ, Brennan RA. Metabolic substrate utilization by a tumour cell line which induces cachexia in vivo. Br J Cancer (1986) 54(4):601-6. doi:10.1038/bjc.1986.215.
35. Sawai M, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K. Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency. Anticancer Res (2004) 24(4):2213-7.
36. Oleksyszyn J. The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug metformin, as a potential anti-cancer therapy. Med Hypotheses (2011) 77(2):171-3. doi:10.1016/j.mehy.2011.04.001.
37. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer (2003) 89(7):1375-82. doi:10.1038/sj.bjc.6601269.
38. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) (2007) 4:5. doi:10.1186/1743-7075-4-5.
39. Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc (1995) 95(6):693-7. doi:10.1016/S0002-8223(95)00189-1.
40. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr (1995) 14(2):202-8. doi:10.1080/07315724.1995.10718495.
41. Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res (2004) 10(16):5622-9. doi:10.1158/1078-0432.CCR-04-0308.
42. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One (2012) 7(5):e36197. doi:10.1371/journal.pone.0036197.
43. Camarero N, Mascaro C, Mayordomo C, Vilardell F, Haro D, Marrero PF. Ketogenic HMGCS2 Is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer. Mol Cancer Res (2006) 4(9):645-53. doi:10.1158/1541-7786.MCR-05-0267.
44. Pacifici M, Peruzzi F. Isolation and culture of rat embryonic neural cells: a quick protocol. J Vis Exp (2012) (63):e3965. doi:10.3791/3965.
45. Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM, et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J (2001) 356(Pt 3):899-906. doi:10.1042/0264-6021:3560899.
46. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem (1989) 182(1):16-9. doi:10.1016/0003-2697(89)90710-0.
47. Drukala J, Urbanska K, Wilk A, Grabacka M, Wybieralska E, Del Valle L, et al. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha-mediated inhibition of glioma cell motility in vitro. Mol Cancer (2010) 9:159. doi:10.1186/1476-4598-9-159.
48. Wilk A, Wyczechowska D, Zapata A, Dean M, Mullinax J, Marrero L, et al. Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death. Mol Cell Biol (2015) 35(1):182-98. doi:10.1128/MCB.00562-14.
49. Wilk A, Urbanska K, Grabacka M, Mullinax J, Marcinkiewicz C, Impastato D, et al. Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle (2012) 11(14):2660-71. doi:10.4161/cc.21015.
50. Feijo Delgado F, Cermak N, Hecht VC, Son S, Li Y, Knudsen SM, et al. Intracellular water exchange for measuring the dry mass, water mass and changes in chemical composition of living cells. PLoS One (2013) 8(7):e67590. doi:10.1371/journal.pone.0067590.
51. Oosterveer MH, Grefhorst A, van Dijk TH, Havinga R, Staels B, Kuipers F, et al. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem (2009) 284(49):34036-44. doi:10.1074/jbc.M109.051052.
52. Boros LG, Lee PW, Brandes JL, Cascante M, Muscarella P, Schirmer WJ, et al. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med Hypotheses (1998) 50(1):55-9. doi:10.1016/S0306-9877(98)90178-5.
53. Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell (2014) 5(8):592-602. doi:10.1007/s13238-014-0082-8.
54. Pierce MW, Palmer JL, Keutmann HT, Hall TA, Avruch J. The insulin-directed phosphorylation site on ATP-citrate lyase is identical with the site phosphorylated by the cAMP-dependent protein kinase in vitro. J Biol Chem (1982) 257(18):10681-6.
55. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem (2002) 277(37):33895-900. doi:10.1074/jbc.M204681200.
56. Potapova IA, El-Maghrabi MR, Doronin SV, Benjamin WB. Phosphorylation of recombinant human ATP:citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP:citrate lyase by phosphorylated sugars. Biochemistry (2000) 39(5):1169-79. doi:10.1021/bi992159y.
57. Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res (2006) 12(10):3028-36. doi:10.1158/1078-0432.CCR-05-2556.
58. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate "fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 9(17):3506-14. doi:10.4161/cc.9.17.12731.
59. Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe R, Howell A, et al. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol Ther (2011) 12(12):1101-13. doi:10.4161/cbt.12.12.18703.
60. Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F. Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle (2012) 11(21):3956-63. doi:10.4161/cc.22136.
61. Roeder LM, Poduslo SE, Tildon JT. Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res (1982) 8(4):671-82. doi:10.1002/jnr.490080412.
62. Hildebrandt L, Spennetta T, Ackerman R, Elson C, Shrago E. Acyl CoA and lipid synthesis from ketone bodies by the extramitochondrial fraction of hepatoma tissue. Biochem Biophys Res Commun (1996) 225(1):307-12. doi:10.1006/bbrc.1996.1171.
63. Hildebrandt LA, Spennetta T, Elson C, Shrago E. Utilization and preferred metabolic pathway of ketone bodies for lipid synthesis by isolated rat hepatoma cells. Am J Physiol (1995) 269(1 Pt 1):C22-7.
64. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab (2014) 25(1):42-52. doi:10.1016/j.tem.2013.09.002.
65. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science (2013) 339(6116):211-4. doi:10.1126/science.1227166.
66. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 24(50):7410-25. doi:10.1038/sj.onc.1209086.
67. Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y. A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. PLoS One (2012) 7(1):e30750. doi:10.1371/journal.pone.0030750.
68. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res (1997) 57(19):4242-8.
69. Wen D, Liu D, Tang J, Dong L, Liu Y, Tao Z, et al. Malic enzyme 1 induces epithelial-mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma. Tumour Biol (2015) 36(8):6211-21. doi:10.1007/s13277-015-3306-5.
70. Csanadi A, Kayser C, Donauer M, Gumpp V, Aumann K, Rawluk J, et al. Prognostic value of malic enzyme and ATP-citrate lyase in non-small cell lung cancer of the young and the elderly. PLoS One (2015) 10(5):e0126357. doi:10.1371/journal.pone.0126357.
71. Chang YL, Gao HW, Chiang CP, Wang WM, Huang SM, Ku CF, et al. Human mitochondrial NAD(P)(+)-dependent malic enzyme participates in cutaneous melanoma progression and invasion. J Invest Dermatol (2015) 135(3):807-15. doi:10.1038/jid.2014.385.
72. Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res (2000) 20(6D):5151-4.
73. Rao KN, Elm MS, Kelly RH, Chandar N, Brady EP, Rao B, et al. Hepatic hyperplasia and cancer in rats: metabolic alterations associated with cell growth. Gastroenterology (1997) 113(1):238-48. doi:10.1016/S0016-5085(97)70101-X.
74. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature (2013) 493(7434):689-93. doi:10.1038/nature11776.
75. Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem (2013) 288(18):12967-77. doi:10.1074/jbc.M112.396796.
76. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z, et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep (2014) 7(5):1679-90. doi:10.1016/j.celrep.2014.04.037.
77. Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer (2002) 86(10):1615-21. doi:10.1038/sj.bjc.6600298.
78. Mulrooney TJ, Marsh J, Urits I, Seyfried TN, Mukherjee P. Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS One (2011) 6(3):e18085. doi:10.1371/journal.pone.0018085.
79. Woolf EC, Scheck AC. The ketogenic diet for the treatment of malignant glioma. J Lipid Res (2015) 56(1):5-10. doi:10.1194/jlr.R046797.
80. Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab (2015) 3:3. doi:10.1186/s40170-015-0129-1.